



Express Mail Label No. EV 956 470 659 US Dated: December 15, 2006

Docket No.: BGN-B191CPUSDV  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Jeffrey L. Browning *et al.*

Application No.: 10/077,406

Confirmation No.: 4141

Filed: February 15, 2002

Art Unit: 1646

For: Methods for Inhibiting Lymphotoxin-Beta  
Receptor Signaling

Examiner: E. B. O'Hara

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)**

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

For the Examiner's convenience in reviewing this divisional application, Applicants submit a consolidated PTO Form SB/08, listing all references cited during the prosecution of the parent application. The present application is a divisional applicaiton of U.S. Serial No. 09/000166, filed June 8, 1998 (Atty. Docket No. BGN-B191CPUS). All references listed on the enclosed PTO Form SB/08 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of the references are not enclosed but will be provided upon request.

12/19/2006 AWONDAF1 00000072 120080 1007/406

02 FC:1806 180.00 DA

In accordance with 37 CFR 1.97, Applicants cite commonly owned copending applications and patents directed to related subject matter:

U.S. Patent No.	5,925,351	Issue Date	July 20, 1999
U.S. Patent No.	6,669,941	Issue Date	December 30, 2003
U.S. Patent No.	6,403,087	Issue Date	June 11, 2002
U.S. Serial No.	09/299139	Filing Date	April 23, 1999
U.S. Publication No.	20020197254	Filing Date	October 31, 2001

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. BGNB191CPUSDV.

Dated: December 15, 2006

AEM/CEH/JGS/mch

Respectfully submitted,

By 

Cristin E. Howley/Ph.D.

Registration No.: 55,281

LAHIVE & COCKFIELD, LLP

One Post Office Square

Boston, Massachusetts 02109-2127

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p align="center"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p align="center"><i>(Use as many sheets as necessary)</i></p>				<b>Complete if Known</b>	
				Application Number	10/077,406-Conf. #4141
				Filing Date	February 15, 2002
				First Named Inventor	Jeffrey L. BROWNING
				Art Unit	1646
				Examiner Name	E. B. O'Hara
Sheet	1	of	2	Attorney Docket Number	BGN-B191CPUSDV

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1*	US-5,082,783	01-21-1992	Ernst et al.	
	A2	US 5,925,351	07-20-1999	Browning, et al.	
	A3	US 6,669,941	12-30-2003	Browning, et al.	
	A4	US 6,403,087	6-11-2002	Browning, et al.	
	A5	US 20020197254	12-26-2002	Browning, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1*	WO-94/04679-A1		03-03-1994	Genentech, Inc.	
	B2*	WO-94/13808-A2		06-23-1994	Biogen, Inc., et al.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1*	Androlewicz, Matthew J. et al., "Lymphotoxin is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma," <i>J. of Biol. Chem.</i> , Vol. 267(4):2542-2547 (1992)	
	C2*	Arulanandam, Antonio R.N. et al., "A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice," <i>J. of Exp. Med.</i> , Vol. 177:1439-1450 (1993)	
	C3*	Baens, M. et al., "Construction and Evaluation of a hncDNA Library of Human 12p Transcribed Sequences Derived from a Somatic Cell Hybrid," <i>Genomics</i> , Vol. 16(1):214-218 (1993)	
	C4*	Browning, J.L. et al., "Lymphotoxin and an Associated 33-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma," <i>J. of Immunol.</i> , Vol. 147(4):1230-1237 (1991)	
	C5*	Browning, J.L. et al., "Characterization of Surface Lymphotoxin Forms. Use of specific monoclonal antibodies and soluble receptors," <i>J. of Immunol.</i> , Vol. 154(1):33-46 (1995)	
	C6*	Browning, J.L. et al., "Lymphotoxin Beta, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface," <i>Cell</i> , Vol. 72(6):847-856 (1993)	
	C7*	Browning, J. et al., "Studies of the Differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines," <i>J. of Immunol.</i> , Vol. 143(6):1859-1867 (1989)	
	C8*	Cher, D.J. et al., "Two Types of Murine Helper T Cell Clone. II. Delayed-type hypersensitivity is mediated by TH1 clones," <i>J. of Immunol.</i> , Vol. 138(11):3688-3694 (1987)	
	C9*	Chisholm, P.L. et al., "Monoclonal antibodies to the integrin Alpha-4 subunit inhibit the murine contact hypersensitivity response," <i>Eur. J. Immunol.</i> , Vol. 23(3):682-688 (1993)	

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/077,406-Conf. #4141
				Filing Date	February 15, 2002
				First Named Inventor	Jeffrey L. BROWNING
				Art Unit	1646
				Examiner Name	E. B. O'Hara
Sheet	2	of	2	Attorney Docket Number	BGN-B191CPUSDV

C10*	Crowe et al., "Production of lymphotoxin (LT alpha) and a soluble dimeric form of its receptor using the baculovirus expression system," <i>J. Immunol. Methods</i> , Vol. 168(1):79-89 (1994)	
C11*	Crowe, P.D. et al., "A Lymphotoxin-Beta Specific Receptor," <i>Science</i> , Vol. 264(5159):707-710 (1994)	
C12*	Fägerstam et al., "Surface Plasmon Resonance Detection in Affinity Technologies: BIAcore," <i>Handbook of Affinity Chromatography</i> , Toni Kline, Editor, Vol. 63, pp. 229-252 (1993)	
C13*	Huang, S. et al., "Immune Response in Mice that Lack the Interferon-gamma Receptor," <i>Science</i> , Vol. 259(5102):1742-1745 (1993)	
C14*	Katz, J.D. et al., "T Helper Cell subsets in Insulin-Dependent Diabetes," <i>Science</i> , Vol. 268(5214):1185-1188 (1995)	
C15*	Lane, P. et al., "Activated human T Cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes," <i>Eur. J. Immunol.</i> , Vol. 22(10):2573-2578 (1992)	
C16*	Lawton, P. et al., "Characterization of the Mouse Lymphotoxin-beta Gene," <i>J. of Immunol.</i> , Vol. 154(1):239-246 (1995)	
C17*	Ling, L.E. et al., "Human Type I Interferon Receptor, IFNAR, Is a Heavily Glycosylated 120-130 kD Membrane Protein," <i>J. Interferon and Cytokine Res.</i> , Vol. 15(1):55-61 (1995)	
C18*	Morrissey, Philip J. et al., "CD4+ T Cells That Express High Levels of CD45RB Induce Wasting Disease When Transferred into Congenic Severe Combined Immunodeficient Mice. Disease Development Is Prevented by Cotransfer of Purified CD4+ T Cells," <i>J. Exp. Med.</i> , Vol. 178:237-244 (1993)	
C19*	Morrison, S.L. et al., "In Vitro Antibodies: Strategies for Production and Application," <i>Ann. Rev. Immunol.</i> , Vol. 10:238-265 (1992)	
C20*	Modlin, R.L. et al., "Type 2 cytokines and negative immune regulation in human infections," <i>Current Opinion in Immunol.</i> , Vol. 5(4):511-517 (1993)	
C21*	Powrie, F. et al., "Phenotypically distinct subsets of CD4+ T Cells Induce or Protect from Chronic intestinal inflammation in C. B-17 scid mice," <i>International Immunology</i> , Vol. 5(11):1461-1471 (1993)	
C22*	Powrie, F. et al., "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in scid Mice Reconstituted with CD45RBhi CD4+ T Cells," <i>Immunity</i> , Vol. 1(7):553-562 (1994)	
C23*	Queen, Cary et al., "A humanized antibody that binds to the interleukin 2 receptor," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Vol. 86:10029-10033 (1989)	
C24*	Reed, S.G. et al., "T-cell and cytokine responses in leishmaniasis," <i>Current Opinion in Immunol.</i> , Vol. 5(4):524-531 (1993)	
C25*	Renshaw, Blair R. et al., "Humoral Immune Responses in CD40 Ligand-deficient mice," <i>J. Exp. Med.</i> , Vol. 180:1889-1900 (1994)	
C26*	Roitt et al., "Hypersensitivity - Type I-IV," <i>Immunology</i> , Mosby-Year Book Europe Ltd., 3rd ed., pp. 19.1-22.12 (1993)	
C27*	Romagnani, S., "Lymphokine Production by Human T Cells in Disease States," <i>Ann. Rev. Immunol.</i> , Vol. 12:227-257 (1994)	
C28*	Sayegh, Mohamed H. et al., "CD28-B7 Blockade after Alloantigenic Challenge In Vivo Inhibits Th1 Cytokines by Spares Th2," <i>J. Exp. Med.</i> , Vol. 181:1869-1874 (1995)	
C29*	Trautnecker, A. et al., "Highly Efficient Neutralization of HIV with recombinant CD4-immunoglobulin molecules," <i>Nature</i> , Vol. 339(6219):68-70 (1989)	
C30*	van Dulleman, H.M. et al., "Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> , Vol. 109(1):129-135 (1995)	
C31*	Ware, C.F. et al., "The Ligands and Receptors of the Lymphotoxin System," <i>Current Topics Microbiol. Immunol.</i> , Vol. 198:175-218 (1995)	
C32*	Zhou, M. et al., "Real-Time Measurements of Kinetics of EGF Binding to Soluble EGF Receptor Monomers and Dimers Support the Dimerization Model for Receptor Activation," <i>Biochemistry</i> , Vol. 32(32):8193-8198 (1993)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
-----------------------	--------------------